Clinical trial
Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And…
NCT00471588 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00471588 |
|---|---|
| Title | Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors |
| Official title | Dopamine D2/D3 Receptor Agonist and Antagonist Drug Effects on Fronto-striatal Systems Related to Compulsive Behaviour in Healthy Volunteers and Patients With Addictive and Compulsive Disorders |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Obsessive-Compulsive Disorder |
| Intervention type | Drug |
| Interventions | Pramipexole, Amisulpride |
| Enrollment | 52 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 10, 2007 |
| Last update posted | Sep 15, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: